ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Xyosted Prefilled Autoinjector for Subcutaneous Testosterone Administration
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 128060" data-attributes="member: 13851"><p><span style="font-size: 22px"><strong>Conclusion</strong></span></p><p>Authentic needle and drug-containing devices were used in order to provide a realistic assessment of the potential for limitations of usability with the SCTE-AI device. Results of this usability validation study indicate the low potential for physical harm associated with use of the device. Results of the study indicate that there is residual risk of (i) not checking the expiration date and (ii) holding the device in place long enough to ensure a complete dose.</p><p></p><p>The SCTE-AI is intended for use in the at-home setting by the patient or a non-patient caregiver. It may also be used in hospitals, clinics, long-term care and home care settings on adult patients by health care professionals that includes nurses or <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/home-health-care" target="_blank">home health care</a> professionals who may assist patients to use the device in clinical care or home settings. Compared to trained participants, success rates were lower in untrained users who did not read the IFU (reading the IFU improved success rates). From a clinical perspective, these results suggest that it is ideal for each newly prescribed patient to be provided with a first-use in-office specific training on how to use the SCTE-AI. Subsequent to the first-use training, our results suggest a success rate >80% for patients or caregivers with use of the SCTE-AI with minimal use errors.</p><p></p><p>Overall, the testing in this study is regarded as successful in demonstrating the objective of minimizing the occurrence of preventable use errors. The SCTE-AI device is safe and intuitive to use; is associated with a high rate of injection success, regardless of prior training or experience; and provides patients with an alternative to IM/topical T formulations.</p></blockquote><p></p>
[QUOTE="madman, post: 128060, member: 13851"] [SIZE=22px][B]Conclusion[/B][/SIZE] Authentic needle and drug-containing devices were used in order to provide a realistic assessment of the potential for limitations of usability with the SCTE-AI device. Results of this usability validation study indicate the low potential for physical harm associated with use of the device. Results of the study indicate that there is residual risk of (i) not checking the expiration date and (ii) holding the device in place long enough to ensure a complete dose. The SCTE-AI is intended for use in the at-home setting by the patient or a non-patient caregiver. It may also be used in hospitals, clinics, long-term care and home care settings on adult patients by health care professionals that includes nurses or [URL='https://www.sciencedirect.com/topics/medicine-and-dentistry/home-health-care']home health care[/URL] professionals who may assist patients to use the device in clinical care or home settings. Compared to trained participants, success rates were lower in untrained users who did not read the IFU (reading the IFU improved success rates). From a clinical perspective, these results suggest that it is ideal for each newly prescribed patient to be provided with a first-use in-office specific training on how to use the SCTE-AI. Subsequent to the first-use training, our results suggest a success rate >80% for patients or caregivers with use of the SCTE-AI with minimal use errors. Overall, the testing in this study is regarded as successful in demonstrating the objective of minimizing the occurrence of preventable use errors. The SCTE-AI device is safe and intuitive to use; is associated with a high rate of injection success, regardless of prior training or experience; and provides patients with an alternative to IM/topical T formulations. [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Xyosted Prefilled Autoinjector for Subcutaneous Testosterone Administration
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top